- Developing streamlined approach to reduce cost per patient
by 85%
EDINBURGH, Scotland, April 2,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that it is developing a streamlined and scaled-up
manufacturing process which will increase its treatments capacity
from 52 patient treatments per year to more than 1,000.
This undertaking, which will utilize its current infrastructure,
will provide a cost reduction of 85% per patient treatment.
The Company expects to implement the improved manufacture
process into its current facility in the next 24 months.
"These new initiatives will allow us to increase capacity while
simultaneously reducing the cost of our per patient treatment once
optimized," said Dr. Lauren Bor,
Ph.D., Process Development and Commercialization, Senior Manager.
"This enterprise is necessary to address the challenging operating
landscape in cell therapy and better position TC BioPharm both
economically and operationally to improve the lives of patients
while creating long-term value for shareholders. One of the
biggest bottlenecks in cell therapy today is the high cost of
manufacturing, which leads to extremely high treatment costs to
patients, and this endeavor should allow TCB to reverse these
issues. We are addressing these issues today to provide a low cost,
high margin therapeutic to patients in the future, which maintains
our leadership position from a first move and best in class
perspective. Additionally, I believe that these developments will
lay the groundwork for commercialization plan and increasing TC
BioPharm's manufacturing footprint."
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the Company's intent or ability to affect any budget
savings or execute on any M&A or capital raising strategy.
These statements are based on management's current assumptions and
are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause the
Company's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including that the proposed issuance of shares may not
be approved by the Company's shareholders. For other important
factors that could cause actual results to differ materially from
the forward-looking statements in this press release, please see
the risks and uncertainties identified under the heading "Risk
Factors" in our Annual Report on Form 20-F for the year ended
December 31, 2022, and our other
reports filed with the SEC, all of which is available on the
Company's Investor Relations website at www.tcbiopharm.com and on
the SEC website at www.sec.gov. All forward-looking statements
reflect the Company's beliefs and assumptions only as of the date
of this press release. The Company undertakes no obligation to
update forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-increasing-treatment-capacity-with-expanded-manufacturing-process-302105453.html
SOURCE TC BioPharm